BREAKING NEWS: CDC committee is delaying vote on whether or not to recommend lifting the Johnson & Johnson vaccine hiatus as more data needs to be collected on side effects
- The Advisory Committee on Immunization Practices met on Wednesday to discuss the Johnson & Johnson coronavirus vaccine
- It came after the CDC and FDA recommended halting the introduction of the vaccine after multiple reports of rare but serious blood clots
- The committee delayed its vote to a later date as members wanted more dates before proceeding with a decision
A committee from the Centers for Disease Control and Prevention (CDC) has postponed its vote on whether or not to recommend lifting the Johnson & Johnson coronavirus vaccine hiatus.
The meeting came after the CDC and the US Food and Drug Administration (FDA) suggested that doctors stop using the shot after nine reports of rare but serious blood clots from 7.2 million vaccinations.
Two reports were published in clinical trials and seven after the vaccine was approved for approval for emergency use.
Eight were among women aged 18 to 59 years. One woman died and two are currently in critical condition.
Members of the Advisory Committee on Immunization Practices (ACIP), which develops guidelines for vaccine administration and schedules, apparently wanted more data before proceeding with a decision.
“ACIP does not want to vote or put motions on the table to vote on an amendment to the current recommendation,” the committee wrote in a statement.
The group will meet again in seven to ten days. During this time, members have time to review a better risk assessment. During this time, J & J’s stitch continues to pause.
The CDC’s Advisory Committee on Immunization Practices is delaying its vote on recommendations on the Johnson & Johnson vaccine pending further data (file image).
During the meeting, J&J officials said they believe the benefits of their vaccine outweigh the risks.
However, they suggested that those who administer the shots should be made aware of possible blood clots and be ready to respond when a patient develops them.
Dr. William Schaffner, professor of preventive medicine and infectious diseases at Vanderbilt University Medical Center and a member of ACIP, told DailyMail.com that when the group meets, they will make one of four decisions.
“They could extend the break, continue the vaccine, discontinue the vaccine, or keep using the vaccine in certain groups,” he said.
This is breaking news and will be updated.